Buchumschlag

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Background - Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma and other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zimmer, Lisa (VerfasserIn) , Goldinger, Simone M. (VerfasserIn) , Hofmann, Lars Georg Emre (VerfasserIn) , Loquai, Carmen (VerfasserIn) , Ugurel, Selma (VerfasserIn) , Thomas, Ioannis (VerfasserIn) , Schmidgen, Maria Isabel (VerfasserIn) , Gutzmer, Ralf (VerfasserIn) , Utikal, Jochen (VerfasserIn) , Göppner, Daniela (VerfasserIn) , Hassel, Jessica C. (VerfasserIn) , Meier, Friedegund (VerfasserIn) , Tietze, Julia K. (VerfasserIn) , Forschner, Andrea Lydia (VerfasserIn) , Weishaupt, Carsten (VerfasserIn) , Leverkus, Martin (VerfasserIn) , Wahl, Renate Ursula (VerfasserIn) , Dietrich, Ursula (VerfasserIn) , Garbe, Claus (VerfasserIn) , Kirchberger, Michael Constantin (VerfasserIn) , Eigentler, Thomas (VerfasserIn) , Berking, Carola (VerfasserIn) , Gesierich, Anja Heike (VerfasserIn) , Krackhardt, Angela (VerfasserIn) , Schadendorf, Dirk (VerfasserIn) , Schuler, Gerold (VerfasserIn) , Dummer, Reinhard (VerfasserIn) , Heinzerling, Lucie (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 13 April 2016
In: European journal of cancer
Year: 2016, Jahrgang: 60, Pages: 210-225
ISSN:1879-0852
DOI:10.1016/j.ejca.2016.02.024
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.ejca.2016.02.024
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001507
Volltext
Verfasserangaben:Lisa Zimmer, Simone M. Goldinger, Lars Hofmann, Carmen Loquai, Selma Ugurel, Ioannis Thomas, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Andrea Forschner, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling
Beschreibung
Zusammenfassung:Background - Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma and other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects can involve skin, gastrointestinal tract, liver, the endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential. - Methods and findings - In total, 496 patients with metastatic melanoma from 15 skin cancer centres were treated with pembrolizumab or nivolumab. Two hundred forty two side-effects in 138 patients have been analysed. In 77 of the 138 patients side-effects affected the nervous system, respiratory tract, musculoskeletal system, heart, blood and eyes. Not yet reported side-effects such as meningo-(radiculitis), polyradiculitis, cardiac arrhythmia, asystolia, and paresis have been observed. Rare and difficult to manage side-effects such as myasthenia gravis are described in detail. - Conclusion - Anti-PD-1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
Beschreibung:Gesehen am 02.07.2019
Beschreibung:Online Resource
ISSN:1879-0852
DOI:10.1016/j.ejca.2016.02.024

Ähnliche Einträge